[伊马替尼——慢性髓性白血病新的分子治疗可能性。IRIS研究] - Suppr

Suppr

超能文献

[Imatinib-New, molecular therapeutic possibility in chronic myeloid leukemia. The IRIS Study].

作者信息

Berger U, Hehlmann R

机构信息

III. Medizinische Universitätsklinik, Klinikum Mannheim der Universität Heidelberg.

出版信息

Internist (Berl). 2004 Jan;45(1):102-3. doi: 10.1007/s00108-003-1085-3.

DOI:10.1007/s00108-003-1085-3

PMID:14735248

Abstract

摘要

相似文献

[Imatinib-New, molecular therapeutic possibility in chronic myeloid leukemia. The IRIS Study].[伊马替尼——慢性髓性白血病新的分子治疗可能性。IRIS研究]

Internist (Berl). 2004 Jan;45(1):102-3. doi: 10.1007/s00108-003-1085-3.

[Imatinib combination therapies--the new CML Study 4].伊马替尼联合疗法——新的慢性粒细胞白血病研究4

Dtsch Med Wochenschr. 2002 Oct 18;127(42):224-6.

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.伊马替尼联合聚乙二醇干扰素 α-2a 治疗慢性髓性白血病。

N Engl J Med. 2010 Dec 23;363(26):2511-21. doi: 10.1056/NEJMoa1004095.

Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.一项前瞻性2期研究的结果，该研究将甲磺酸伊马替尼与阿糖胞苷联合用于治疗慢性期费城染色体阳性慢性粒细胞白血病患者。

Blood. 2003 Dec 15;102(13):4298-305. doi: 10.1182/blood-2003-04-1010. Epub 2003 Aug 21.

High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial.伊马替尼治疗干扰素 α 加阿糖胞苷后的持久缓解率高：来自国际干扰素和 STI571（IRIS）随机研究的结果。

Haematologica. 2009 Dec;94(12):1669-75. doi: 10.3324/haematol.2009.010629. Epub 2009 Jul 31.

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.大多数接受伊马替尼治疗的患者达到了深度分子反应，该反应可预测生存，并且通过优化的高剂量伊马替尼更快实现：来自随机 CML-研究 IV 的结果。

J Clin Oncol. 2014 Feb 10;32(5):415-23. doi: 10.1200/JCO.2013.49.9020. Epub 2013 Dec 2.

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.聚乙二醇干扰素 α2b 联合伊马替尼可提高低危或中危慢性髓性白血病患者的分子反应率。

Blood. 2011 Sep 22;118(12):3228-35. doi: 10.1182/blood-2011-02-336685. Epub 2011 Jun 17.

[Molecular response with triple therapy in patients with chronic myeloid leukemia].

Rev Med Inst Mex Seguro Soc. 2014 May-Jun;52(3):262-5.

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.接受伊马替尼治疗的慢性髓性白血病患者的五年随访

N Engl J Med. 2006 Dec 7;355(23):2408-17. doi: 10.1056/NEJMoa062867.

[Current therapy concepts in chronic myeloid leukemia. Study IV of the German CML Study Group].[慢性髓性白血病的当前治疗理念。德国慢性髓性白血病研究组的第四项研究]

Internist (Berl). 2002 Oct;43(10):1228, 1231-8, 1241-4. doi: 10.1007/s00108-002-0706-6.

本文引用的文献

Current CML therapy: progress and dilemma.当前慢性粒细胞白血病的治疗：进展与困境

Leukemia. 2003 Jun;17(6):1010-2. doi: 10.1038/sj.leu.2402951.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.伊马替尼与干扰素和小剂量阿糖胞苷治疗新诊断慢性期慢性髓性白血病的比较

N Engl J Med. 2003 Mar 13;348(11):994-1004. doi: 10.1056/NEJMoa022457.

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.在α干扰素治疗失败后接受伊马替尼治疗的慢性期慢性髓性白血病患者中，早期BCR-ABL mRNA转录水平的降低预示着细胞遗传学反应。

Leukemia. 2002 Sep;16(9):1579-83. doi: 10.1038/sj.leu.2402680.

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.慢性髓性白血病与α干扰素：完全细胞遗传学缓解者的研究

Blood. 2001 Nov 15;98(10):3074-81. doi: 10.1182/blood.v98.10.3074.

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.一种用于接受α干扰素治疗的慢性髓性白血病患者生存情况的新预后评分系统。慢性粒细胞白血病协作预后因素项目组写作委员会。

J Natl Cancer Inst. 1998 Jun 3;90(11):850-8. doi: 10.1093/jnci/90.11.850.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验